Literature DB >> 23024061

Increased surfactant protein D fails to improve bacterial clearance and inflammation in serpinB1-/- mice.

J Michael Stolley1, Dapeng Gong, Kalamo Farley, Picheng Zhao, Jessica Cooley, Erika C Crouch, Charaf Benarafa, Eileen Remold-O'Donnell.   

Abstract

Previously, we described the protective role of the neutrophil serine protease inhibitor serpinB1 in preventing early mortality of Pseudomonas aeruginosa lung infection by fostering bacterial clearance and limiting inflammatory cytokines and proteolytic damage. Surfactant protein D (SP-D), which maintains the antiinflammatory pulmonary environment and mediates bacterial removal, was degraded in infected serpinB1-deficient mice. Based on the hypothesis that increased SP-D would rescue or mitigate the pathological effects of serpinB1 deletion, we generated two serpinB1(-/-) lines overexpressing lung-specific rat SP-D and inoculated the mice with P. aeruginosa. Contrary to predictions, bacterial counts in the lungs of SP-D(low)serpinB1(-/-) and SP-D(high) serpinB1(-/-) mice were 4 logs higher than wild-type and not different from serpinB1(-/-) mice. SP-D overexpression also failed to mitigate inflammation (TNF-α), lung injury (free protein, albumin), or excess neutrophil death (free myeloperoxidase, elastase). These pathological markers were higher for infected SP-D(high)serpinB1(-/-) mice than for serpinB1(-/-) mice, although the differences were not significant after controlling for multiple comparisons. The failure of transgenic SP-D to rescue antibacterial defense of serpinB1-deficient mice occurred despite 5-fold or 20-fold increased expression levels, largely normal structure, and dose-dependent bacteria-aggregating activity. SP-D of infected wild-type mice was intact in 43-kD monomers by reducing SDS-PAGE. By contrast, proteolytic fragments of 35, 17, and 8 kD were found in infected SP-D(low)serpinB1(-/-), SP-D(high) serpinB1(-/-) mice, and serpinB1(-/-) mice. Thus, although therapies to increase lung concentration of SP-D may have beneficial applications, the findings suggest that therapy with SP-D may not be beneficial for lung inflammation or infection if the underlying clinical condition includes excess proteolysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23024061      PMCID: PMC3547094          DOI: 10.1165/rcmb.2012-0145OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  45 in total

1.  Pulmonary surfactant in cystic fibrosis.

Authors:  M Griese; P Birrer; A Demirsoy
Journal:  Eur Respir J       Date:  1997-09       Impact factor: 16.671

2.  The serpin MNEI inhibits elastase-like and chymotrypsin-like serine proteases through efficient reactions at two active sites.

Authors:  J Cooley; T K Takayama; S D Shapiro; N M Schechter; E Remold-O'Donnell
Journal:  Biochemistry       Date:  2001-12-25       Impact factor: 3.162

3.  Genetic element from human surfactant protein SP-C gene confers bronchiolar-alveolar cell specificity in transgenic mice.

Authors:  S W Glasser; T R Korfhagen; S E Wert; M D Bruno; K M McWilliams; D K Vorbroker; J A Whitsett
Journal:  Am J Physiol       Date:  1991-10

4.  Decreased surfactant protein A in patients with bacterial pneumonia.

Authors:  R P Baughman; R I Sternberg; W Hull; J A Buchsbaum; J Whitsett
Journal:  Am Rev Respir Dis       Date:  1993-03

5.  Lung surfactant proteins A and D can inhibit specific IgE binding to the allergens of Aspergillus fumigatus and block allergen-induced histamine release from human basophils.

Authors:  T Madan; U Kishore; A Shah; P Eggleton; P Strong; J Y Wang; S S Aggrawal; P U Sarma; K B Reid
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

6.  Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis.

Authors:  A D Postle; A Mander; K B Reid; J Y Wang; S M Wright; M Moustaki; J O Warner
Journal:  Am J Respir Cell Mol Biol       Date:  1999-01       Impact factor: 6.914

7.  Recombinant human Monocyte/Neutrophil elastase inhibitor protects rat lungs against injury from cystic fibrosis airway secretions.

Authors:  D D Rees; R A Rogers; J Cooley; R J Mandle; D M Kenney; E Remold-O'Donnell
Journal:  Am J Respir Cell Mol Biol       Date:  1999-01       Impact factor: 6.914

8.  Surfactant content in children with inflammatory lung disease.

Authors:  A M LeVine; A Lotze; S Stanley; C Stroud; R O'Donnell; J Whitsett; M M Pollack
Journal:  Crit Care Med       Date:  1996-06       Impact factor: 7.598

Review 9.  Structure, biologic properties, and expression of surfactant protein D (SP-D).

Authors:  E C Crouch
Journal:  Biochim Biophys Acta       Date:  1998-11-19

10.  Molecular structure of pulmonary surfactant protein D (SP-D).

Authors:  E Crouch; A Persson; D Chang; J Heuser
Journal:  J Biol Chem       Date:  1994-06-24       Impact factor: 5.157

View more
  1 in total

Review 1.  Surfactant Protein D in Respiratory and Non-Respiratory Diseases.

Authors:  Grith L Sorensen
Journal:  Front Med (Lausanne)       Date:  2018-02-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.